mRNA |
navitoclax:pluripotin (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.014 |
0.7 |
mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.014 |
0.7 |
mRNA |
COL-3 |
CTRPv2 |
pan-cancer |
AAC |
-0.015 |
0.7 |
mRNA |
BRD-K44224150 |
CTRPv2 |
pan-cancer |
AAC |
0.03 |
0.7 |
mRNA |
Vorinostat |
gCSI |
pan-cancer |
AAC |
0.07 |
0.7 |
mRNA |
VX-680 |
CTRPv2 |
pan-cancer |
AAC |
0.041 |
0.7 |
mRNA |
ML162 |
CTRPv2 |
pan-cancer |
AAC |
0.013 |
0.7 |
mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.012 |
0.7 |
mRNA |
WZ4002 |
CTRPv2 |
pan-cancer |
AAC |
-0.016 |
0.7 |
mRNA |
HLI 373 |
CTRPv2 |
pan-cancer |
AAC |
-0.013 |
0.7 |